A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension

British Journal of Ophthalmology

Volumn 88, Issue 2, 2004, Pages 199-203

  Diestelhorst, M ^a   Larsson, L I ^b,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Pharmacia Corporation   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; EYE IRRITATION; FEMALE; HUMAN; HYPERTRICHOSIS; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VISUAL DISORDER;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL; TREATMENT OUTCOME;

EID: 0942290466     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2003.018234     Document Type: Article

References (25)

1. Alward WLM. Medical management of glaucoma. N Engl J Med 1998;339:1298-307.
2. Lundberg LU, Thygesen J, Damgaard-Jensen L, et al. Glaucoma patients treated by practicing ophthalmologists in Denmark. Estimated number of patients and the extent of visual field defects. Ugeskr Laeger 2000;162:3028-33.
3. Realini T, Fechtner RD. 56,000 ways to treat glaucoma. Ophthalmology 2002;109:1955-6.
4. Arici MK, Sayici M, Toker M, et al. A short-term study of the additive effect of timolol and brimonidine on intraocular pressure. Eye 2002;16:39-43.
5. Bucci MG for the Italian Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. J Glaucoma 1999;8:24-30.
6. Diestelhorst M, Nordmann J-P, Toris CB. Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy. Surv Ophthalmol 2002;47(Suppl 1):S155-61.
7. 2a analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994;78:899-902.
8. Zimmerman TJ, Kaufman HE. Timolol: a β-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977;95:601-4.
9. Zimmerman TJ, Harbin R, Pett M, et al. Timolol and facility of outflow. Invest Ophthalmol Vis Sci 1977;16:623-4.
10. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol 1978;96:2045-8.
11. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995;102:1743-52.
12. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996;103:138-47.
13. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-37.
14. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304.
15. 2α-1-isopropyl ester to timolol in glaucoma patients. Ophthalmology 1991;98:1079-82.
16. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26:233-6.
17. Weinreb RN. Compliance with medical treatment of glaucoma. J Glaucoma 1992;1:134-6.
18. Diestelhorst M, Almegård B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Groefe's Arch Clin Exp Ophthalmol 1998;236:577-81.
19. Pfeiffer N, and The European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefe's Arch Clin Exp Ophthalmol 2002;240:893-9.
20. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy versus monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120:915-22.
21. Larsson L-I. The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. Acta Ophthalmol Scand 2001;79:125-8.
22. Konstas AGP, Maltezos AC, Gandi S, et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 1999;128:15-20.
23. Konstas AGP, Nakos E, Tersis I, et al. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol 2002;133:753-7.
24. Akafo SK, Thompson JR, Rosenthal AR. A cross-over trial comparing once daily levobunolol with once and twice daily timolol. Eur J Ophthalmol 1995;5:172-6.
25. Soll DB. Evaluation of timolol in chronic open-angle glaucoma: once a day vs twice a day. Arch Ophthalmol 1980;98:2178-81.